JPRN-UMIN000013055已完成未知
Erlotinib in non- or light-smoker patients with NSCLC harvoring wild type EGFR and wild type ALK - Erlotinib in light-smoking lung adenocarcinoma with wild EGFR and ALK
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 55
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Concomitant interstitial pneumonotis Concomitant other advanced cancer Smoing index > 100
研究者
相似试验
已完成
不适用
Evaluation of efficacy of erlotinib in patients with untreated, EGFR mutation positive, untreated-locally advanced NSCLC.ntreated, EGFR mutation positive, untreated-locally advanced NSCLC.JPRN-UMIN000011467agasaki Thoracic Oncology Group10
招募中
2 期
A phase II study of erlotinib for patients with pretreated non-small cell lung cancer with brain metastasis and sensitive EGFR mutations.on-small cell lung cancerJPRN-UMIN000002861Shizuoka General Hospital Respiratory center24
已完成
不适用
PhaseII study of erlotinib in previously treated non-small cell lung cancer (NSCLC) with wild type EGFRPre-treated non-small cell lung cancer with wild type EGFR and occurred in never or light smokerJPRN-UMIN000005491Hiroshima citizens hospital Department of Medical Oncology40
进行中（未招募）
不适用
A Phase II Study of Erlotinib in Patients with Polycythaemia Vera and Essential ThrombocythemiaEUCTR2007-007335-99-DKHerlev Hospital, Dept. of Haematology (L121)10
已完成
2 期
Phase II study of Erlotinib in previously treated advanced non-small cell lung cancer patients with carcinomatous meningitison-small cell lung cancerJPRN-UMIN000007020ung Oncology Group in Kyushu, Japan (LOGIK)32